Novel therapies.

New hope.

We’re developing treatments that target human disease at the molecular level.

What we do

Our focus? Working with ribose-based molecules, we use structure-guided design to generate safe and effective drug candidates—like our oral ENPP1 inhibitor treatment that’s currently in Phase 2 clinical trials.

A close-up view of a lab sample in a researcher’s hand.

Why we do it

We’re driven to find solutions for unmet medical needs—particularly in oncology and virology—making discoveries that can result in first-in-class drugs and best-in-class treatments and recovery outcomes.

How we do it

We combine uncommon chemistry and structural biology expertise with novel protein targets, and the outcome is a not-too-distant future with entirely new classes of disease-fighting drugs. 

Several researchers in a lab using equipment and working with samples.

Our science

High methodology standards

The Riboscience Nucleoside Platform explores promising ribose-derived molecules that access unique targets in human disease—and that can ultimately produce treatments that are more effective, safe, overcome immune tolerance, and could even induce/activate immunity.

Employee working on a laptop computer

Our approach

Patient impact is our biggest metric

We generate high-quality data with our proprietary library of nucleosides to find therapeutics with the highest potential for safe, beneficial treatments that improve people’s lives.

More resources

partnership icon

Contact us

employee icon

Join our team

news icon

News &
publications

Discover more about Riboscience